NAOVNanoVibronix, Inc.

Nasdaq nanovibronix.com


$ 0.63 $ -0.01 (-1.88 %)    

Friday, 16-Aug-2024 10:00:11 EDT
QQQ $ 481.15 $ 6.24 (1.31 %)
DIA $ 409.09 $ 2.37 (0.58 %)
SPY $ 559.11 $ 5.30 (0.96 %)
TLT $ 97.90 $ 0.45 (0.46 %)
GLD $ 231.62 $ -0.38 (-0.16 %)
$ 0.604
$ 0.59 x 100
-- x --
-- - --
$ 0.52 - $ 4.23
13,897
na
1.68M
$ 0.97
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2024 06-30-2024 10-Q
2 05-15-2024 03-31-2024 10-Q
3 04-08-2024 12-31-2023 10-K
4 11-13-2023 09-30-2023 10-Q
5 08-11-2023 06-30-2023 10-Q
6 05-15-2023 03-31-2023 10-Q
7 04-17-2023 12-31-2022 10-K
8 11-14-2022 09-30-2022 10-Q
9 08-15-2022 06-30-2022 10-Q
10 05-16-2022 03-31-2022 10-Q
11 04-14-2022 12-31-2021 10-K
12 11-15-2021 09-30-2021 10-Q
13 08-16-2021 06-30-2021 10-Q
14 05-24-2021 03-31-2021 10-Q
15 04-15-2021 12-31-2020 10-K
16 11-16-2020 09-30-2020 10-Q
17 08-19-2020 06-30-2020 10-Q
18 07-06-2020 03-31-2020 10-Q
19 05-20-2020 12-31-2019 10-K
20 11-19-2019 09-30-2019 10-Q
21 08-14-2019 06-30-2019 10-Q
22 05-20-2019 03-31-2019 10-Q
23 04-15-2019 12-31-2018 10-K
24 11-14-2018 09-30-2018 10-Q
25 08-14-2018 06-30-2018 10-Q
26 05-15-2018 03-31-2018 10-Q
27 03-29-2018 12-31-2017 10-K
28 11-14-2017 09-30-2017 10-Q
29 08-14-2017 06-30-2017 10-Q
30 05-15-2017 03-31-2017 10-Q
31 03-31-2017 12-31-2016 10-K
32 11-14-2016 09-30-2016 10-Q
33 08-15-2016 06-30-2016 10-Q
34 05-16-2016 03-31-2016 10-Q
35 03-30-2016 12-31-2015 10-K
36 11-16-2015 09-30-2015 10-Q
37 08-14-2015 06-30-2015 10-Q
38 05-15-2015 03-31-2015 10-Q
39 03-30-2015 12-31-2014 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 nanovibronix-presents-uroshield-clinical-study-at-the-university-of-michigan

NanoVibronix, Inc. (NASDAQ:NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface A...

 nanovibronix-q1-eps-023-up-from-067-yoy-sales-92100k-up-from-35400k-yoy

NanoVibronix (NASDAQ:NAOV) reported quarterly losses of $(0.23) per share. This is a 65.67 percent increase over losses of $(0....

 nanovibronix-and-va-supplier-cb-medical-announce-distribution-agreement-for-theuroshield

NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix," or the "Company"), a medical device company that produces the...

 nanovibronix-announces-painshield-to-be-included-in-department-of-veteran-affairs-fss-contract-award-effective-may-1-2024

Distribution Partner, Delta Medical, Awarded a Five-Year Federal Supply Schedule Contract for PainShield by Department of Veter...

 nanovibronix-issues-letter-to-stockholders

We are committed to our strategic vision of developing, improving and commercializing our distinct and effective therapies, whi...

 nanovibronix-signs-agreement-for-research-and-development-of-next-generation-painshield-and-uroshield

Efforts Focused on Adding Therapeutic Functionality and Reducing CostsNanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" ...

 nanovibronix-shares-resume-trade
NanoVibronix Shares Resume Trade
01/25/2024 16:14:12

 nanovibronix-announces-agreement-for-clinical-study-of-uroshield-at-the-university-of-michigan

Gathering Additional Clinical Evidence to Support Application to FDA for Permanent ClearanceNanoVibronix, Inc. (NASDAQ:NAOV), a...

 nanovibronix-regains-nasdaq-compliance

NanoVibronix, Inc., (NASDAQ:NAOV) (the "Company"), a medical device company that produces the UroShield® and PainShield...

 nanovibronix-uroshield-products-available-on-nhs-drug-tariff-effective-november-1

Receives Stocking Order from U.K. Distribution Partner in Anticipation of Increasing DemandNanoVibronix, Inc. (Nasdaq: NAOV), a...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION